莫雷西嗪合用倍他乐克治疗良性室性早搏的疗效和安全性

The efficacy and safety of Moricizine combinated Betalac in benign ventricular ectopic beats

目的 :评价莫雷西嗪合用倍他乐克治疗良性室性期前收缩 (室早 )的疗效和安全性。方法 :选择 80例无器质性心脏病变的良性室早患者 ,随机分为两组 ,38例为莫雷西嗪组 (单用组 ) ,4 2例为莫雷西嗪合用倍他乐克组 (合用组 )。分析两组的疗效和不良反应。结果 :单用组和合用组治疗良性室早的有效率分别为 74 %和 81% ,不良反应发生率分别为 37%和 33% ;两组间均无显著性差异。结论 :莫雷西嗪合用倍他乐克是治疗良性室早的一种安全、有效的方法。

AIM: To evaluate efficacy and safety of Moricizine combinated Batalac in benign ventricular ectopic beats.: METHODS: 80 patients with benign ventricular ectopic beats, without structural heart disease were randomly divided into two groups, among whom 38 were assigned to Moricizine group(single group) and 42 to Moricizine combinated Batalac group(combinated group).To analyse effective rate and occurrence rate of adverse reaction in the two groups. RESULTS: The effective rate of single group and combinated group were 74%,81%;the occurrence rate of adverse reaction of single group and combinated group were 37%,33%, respectively. There were no significant difference between the two groups. CONCLUSION: This study demonstrates that Moricizine combinated Batalac is efficent and safe in benign ventricular ectopic beats.